(c) 2024 PillSync.com

Bicalutamide (bicalutamide 50 mg) Dailymed

  1. Human Prescription
  2. Archived
    • May Be Discontinued
      Try Other Labelers
  3. American Health Packaging

Generic: bicalutamide

Bicalutamide tablet, film coated - (bicalutamide 50 mg) image

IMPRINT: ZE 57     SHAPE: round
    COLOR: white

  1. FDA Adverse Reactions

Go PRO for all pill images

1 Indications And Usage


  • Bicalutamide 50 mg is an androgen receptor inhibitor indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D 2 metastatic carcinoma of the prostate.
  • Bicalutamide 150 mg daily is not approved for use alone or with other treatments. ( 1)


Bicalutamide tablets 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D 2 metastatic carcinoma of the prostate.

Bicalutamide tablets 150 mg daily is not approved for use alone or with other treatments [see Clinical Studies ( 14.2)].

2 Dosage And Administration



The recommended dose for bicalutamide therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening). ( 2)


The recommended dose for bicalutamide tablets therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide tablets should be started at the same time as treatment with an LHRH analog.

2.1 Dosage Adjustment in Renal Impairment


No dosage adjustment is necessary for patients with renal impairment [see Use in Specific Populations ( 8.7)].

2.2 Dosage Adjustment in Hepatic Impairment


No dosage adjustment is necessary for patients with mild to moderate hepatic impairment. In patients with severe liver impairment (n=4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary [see Use in Specific Populations ( 8.6)].

3 Dosage Forms And Strengths



50 mg tablets ( 3)


Bicalutamide Tablets, 50 mg for oral administration are white to off-white, round, biconvex, film-coated tablets, imprinted with "ZE 57" in black ink on one side and plain on other side.

4 Contraindications


  • Hypersensitivity ( 4.1)
  • Women ( 4.2)
  • Pregnancy ( 4.3 and 8.1)

4.1 Hypersensitivity


Bicalutamide is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tabletā€™s components. Hypersensitivity reactions including angioneurotic edema and urticaria have been reported [see ADVERSE REACTIONS ( 6.2)].

4.2 Women


Bicalutamide has no indication for women, and should not be used in this population.

4.3 Pregnancy


Bicalutamide may cause fetal harm when administered to a pregnant woman. Bicalutamide is contraindicated in women, including those who are or may become pregnant. There are no studies in pregnant women using bicalutamide. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be appraised of the potential hazard to the fetus [see Use in Specific Populations ( 8.1)].

5 Warnings And Precautions


  • Severe hepatic changes and hepatic failure have been observed rarely. Monitor serum transaminase levels prior to starting treatment with bicalutamide, at regular intervals for the first four months of treatment and periodically thereafter, and for symptoms or signs suggestive of hepatic dysfunction. Use bicalutamide with caution in patients with hepatic impairment. ( 5.1)
  • Gynecomastia and breast pain have been reported during treatment with bicalutamide 150 mg when used as a single agent. ( 5.2)
  • Bicalutamide is used in combination with a LHRH agonist. LHRH agonists have been shown to cause a reduction in glucose tolerance in males. Consideration should be given to monitoring blood glucose in patients receiving bicalutamide in combination with LHRH agonists. ( 5.3)
  • Monitoring Prostate Specific Antigen (PSA) is recommended. Evaluate for clinical progression if PSA increases. ( 5.4)

5.1 Hepatitis


Rare cases of death or hospitalization due to severe liver injury have been reported post-marketing in association with the use of bicalutamide. Hepatotoxicity in these reports generally occurred within the first three to four months of treatment. Hepatitis or marked increases in liver enzymes leading to drug discontinuation occurred in approximately 1% of bicalutamide patients in controlled clinical trials.

Serum transaminase levels should be measured prior to starting treatment with bicalutamide, at regular intervals for the first four months of treatment, and periodically thereafter. If clinical symptoms or signs suggestive of liver dysfunction occur (e.g., nausea, vomiting, abdominal pain, fatigue, anorexia, "flu-like" symptoms, dark urine, jaundice, or right upper quadrant tenderness), the serum transaminases, in particular the serum ALT, should be measured immediately. If at any time a patient has jaundice, or their ALT rises above two times the upper limit of normal, bicalutamide should be immediately discontinued with close follow-up of liver function.

5.2 Gynecomastia and Breast Pain


In clinical trials with bicalutamide 150 mg as a single agent for prostate cancer, gynecomastia and breast pain have been reported in up to 38% and 39% of patients, respectively.

5.3 Glucose Tolerance


A reduction in glucose tolerance has been observed in males receiving LHRH agonists. This may manifest as diabetes or loss of glycemic control in those with preexisting diabetes. Consideration should therefore be given to monitoring blood glucose in patients receiving bicalutamide in combination with LHRH agonists.

5.4 Laboratory Tests


Regular assessments of serum Prostate Specific Antigen (PSA) may be helpful in monitoring the patientā€™s response. If PSA levels rise during bicalutamide therapy, the patient should be evaluated for clinical progression. For patients who have objective progression of disease together with an elevated PSA, a treatment-free period of antiandrogen, while continuing the LHRH analog, may be considered.

6 Adverse Reactions



Adverse reactions that occurred in more than 10% of patients receiving bicalutamide plus an LHRH-A were: hot flashes, pain (including general, back, pelvic and abdominal), asthenia, constipation, infection, nausea, peripheral edema, dyspnea, diarrhea, hematuria, nocturia and anemia. ( 6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Zydus Pharmaceuticals USA Inc. at 1-877-993-8779 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch


Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

6.1 Clinical Trials Experience


In patients with advanced prostate cancer treated with bicalutamide in combination with an LHRH analog, the most frequent adverse reaction was hot flashes (53%).

In the multicenter, double-blind, controlled clinical trial comparing bicalutamide 50 mg once daily with flutamide 250 mg three times a day, each in combination with an LHRH analog, the following adverse reactions with an incidence of 5% or greater, regardless of causality, have been reported.
Table 1 Incidence of Adverse Reactions (ā‰„ 5% in Either Treatment Group) Regardless of Causality
BodyĀ  System Ā Ā Ā Ā Ā  AdverseĀ  Reaction TreatmentĀ  Group
NumberĀ  ofĀ  PatientsĀ  (%)
BicalutamideĀ  Plus LHRHĀ  Analogue ( n = 401 ) FlutamideĀ  Plus LHRHĀ  Analogue ( n = 407 )
BodyĀ  asĀ  aĀ  Whole
PainĀ (General) 142Ā (35) 127Ā (31)
BackĀ Pain 102Ā (25) 105Ā (26)
Asthenia 89Ā (22) 87Ā (21)
PelvicĀ Pain 85Ā (21) 70Ā (17)
Infection 71Ā (18) 57Ā (14)
AbdominalĀ Pain 46Ā (11) 46Ā (11)
ChestĀ Pain 34Ā (8) 34Ā (8)
Headache 29Ā (7) 27Ā (7)
FluĀ Syndrome 28Ā (7) 30Ā (7)
Cardiovascular
HotĀ Flashes 211Ā (53) 217Ā (53)
Hypertension 34Ā (8) 29Ā (7)
Digestive
Constipation 87Ā (22) 69Ā (17)
Nausea 62Ā (15) 58Ā (14)
Diarrhea 49Ā (12) 107Ā (26)
IncreasedĀ Liver EnzymeĀ Test Increased liver enzyme test includes increases in AST, ALT or both. 30Ā (7) 46Ā (11)
Dyspepsia 30Ā (7) 23Ā (6)
Flatulence 26Ā (6) 22Ā (5)
Anorexia 25Ā (6) 29Ā (7)
Vomiting 24Ā (6) 32Ā (8)
HemicĀ  andĀ  Lymphatic
Anemia Anemia includes anemia, hypochronic-and iron deficiency anemia. 45Ā (11) 53Ā (13)
MetabolicĀ  andĀ  Nutritional
PeripheralĀ Edema 53Ā (13) 42Ā (10)
WeightĀ Loss 30Ā (7) 39Ā (10)
Hyperglycemia 26Ā (6) 27Ā (7)
AlkalineĀ PhosphataseĀ Increased 22Ā (5) 24Ā (6)
WeightĀ Gain 22Ā (5) 18Ā (4)
Muscoloskeletal
BoneĀ Pain 37Ā (9) 43Ā (11)
Myasthenia 27Ā (7) 19Ā (5)
Arthritis 21Ā (5) 29Ā (7)
Pathological Fracture 17Ā (4) 32Ā (8)
NervousĀ  System
Dizziness 41Ā (10) 35Ā (9)
Paresthesia 31Ā (8) 40Ā (10)
Insomnia 27Ā (7) 39Ā (10)
Anxiety 20Ā (5) 9Ā (2)
Depression 16Ā (4) 33Ā (8)
RespiratoryĀ  System
Dyspnea 51Ā (13) 32Ā (8)
CoughĀ Increased 33Ā (8) 24Ā (6)
Pharyngitis 32Ā (8) 23Ā (6)
Bronchitis 24Ā (6) 22Ā (3)
Pneumonia 18Ā (4) 19Ā (5)
Rhinitis 15Ā (4) 22Ā (5)
SkinĀ  andĀ  Appendages
Rash 35Ā (9) 30Ā (7)
Sweating 25Ā (6) 20Ā (5)
Urogenital
Nocturia 49Ā (12) 55Ā (14)
Hematuria 48Ā (12) 26Ā (6)
UrinaryĀ TractĀ Infection 35Ā (9) 36Ā (9)
Gynecomastia 36Ā (9) 30Ā (7)
Impotence 27Ā (7) 35Ā (9)
BreastĀ Pain 23Ā (6) 15Ā (4)
UrinaryĀ FrequencyĀ  23Ā (6) 29Ā (7)
UrinaryĀ Ā Retention 20Ā (5) 14Ā (3)
UrinaryĀ Impaired 19Ā (5) 15Ā (4)
UrinaryĀ Incontinence 15Ā (4) 32Ā (8)

Other adverse reactions (greater than or equal to 2%, but less than 5%) reported in the bicalutamide-LHRH analog treatment group are uled below by body system and are in order of decreasing frequency within each body system regardless of causality.

Body as a Whole:

Neoplasm; Neck Pain; Fever; Chills; Sepsis; Hernia; Cyst

Cardiovascular:

Angina Pectoris; Congestive Heart Failure; Myocardial Infarct; Heart Arrest; Coronary Artery Disorder; Syncope

Digestive:

Melena; Rectal Hemorrhage; Dry Mouth; Dysphagia; Gastrointestinal Disorder; Periodontal Abscess; Gastrointestinal Carcinoma

Metabolic and Nutritional:

Edema; BUN Increased; Creatinine Increased; Dehydration; Gout; Hypercholesteremia

Musculoskeletal:

Myalgia; Leg Cramps

Nervous:

Hypertonia; Confusion; Somnolence; Libido Decreased; Neuropathy; Nervousness

Respiratory:

Lung Disorder; Asthma; Epistaxis; Sinusitis

Skin and Appendages:

Dry Skin; Alopecia; Pruritus; Herpes Zoster; Skin Carcinoma; Skin Disorder

Special Senses:

Cataract specified

Urogenital:

Dysuria; Urinary Urgency; Hydronephrosis; Urinary Tract Disorder

Abnormal Laboratory Test Values

Laboratory abnormalities including elevated AST, ALT, bilirubin, BUN, and creatinine and decreased hemoglobin and white cell count have been reported in both bicalutamide-LHRH analog treated and flutamide-LHRH analog treated patients.

6.2 Postmarketing Experience


The following adverse reactions have been identified during postapproval use of bicalutamide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Uncommon cases of hypersensitivity reactions, including angioneurotic edema and urticaria [see CONTRAINDICATIONS ( 4.1)], and uncommon cases of interstitial lung disease, including interstitial pneumonitis and pulmonary fibrosis, have been reported with bicalutamide.

Reduction in glucose tolerance, manifesting as diabetes or a loss of glycemic control in those with pre-existing diabetes, has been reported during treatment with LHRH agonists.

7 Drug Interactions


  • R-bicalutamide is an inhibitor of CYP 3A4; therefore, caution should be used when bicalutamide is co-administered with CYP 3A4 substrates. ( 7)
  • Prothrombin times should be closely monitored in patient already receiving coumarin anticoagulants who are started on bicalutamide. ( 7)


Clinical studies have not shown any drug interactions between bicalutamide and LHRH analogs (goserelin or leuprolide). There is no evidence that bicalutamide induces hepatic enzymes.

In vitro studies have shown that R-bicalutamide is an inhibitor of CYP 3A4 with lesser inhibitory effects on CYP 2C9, 2C19 and 2D6 activity. Clinical studies have shown that with co-administration of bicalutamide, mean midazolam (a CYP 3A4 substrate) levels may be increased 1.5 fold (for C max) and 1.9 fold (for AUC). Hence, caution should be exercised when bicalutamide is co-administered with CYP 3A4 substrates.

In vitro protein-binding studies have shown that bicalutamide can displace coumarin anticoagulants from binding sites. Prothrombin times should be closely monitored in patients already receiving coumarin anticoagulants who are started on bicalutamide and adjustment of the anticoagulant dose may be necessary.

8 Use In Specific Populations


  • Pediatric patients: Labeling describing pediatric clinical studies for bicalutamide is approved for AstraZeneca Pharmaceuticals LP's bicalutamide. However, due to AstraZeneca Pharmaceuticals LP's marketing exclusivity rights, a description of those clinical studies is not approved for this bicalutamide labeling. ( 8.4)

8.1 Pregnancy


PREGNANCY CATEGORY X [see CONTRAINDICATIONS ( 4.3)].

Based on its mechanism of action, bicalutamide may cause fetal harm when administered to a pregnant woman. Bicalutamide is contraindicated in women, including those who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.

While there are no human data on the use of bicalutamide in pregnancy and bicalutamide is not for use in women, it is important to know that maternal use of an androgen receptor inhibitor could affect development of the fetus.

In animal reproduction studies, male offspring of rats receiving doses of 10 mg/kg/day (approximately 2/3 of clinical exposure at the recommended dose) and above, were observed to have reduced anogenital distance and hypospadias. These pharmacological effects have been observed with other antiandrogens. No other teratogenic effects were observed in rabbits receiving doses up to 200 mg/kg/day (approximately 1/3 of clinical exposure at the recommended dose) or rats receiving doses up to 250 mg/kg/day (approximately 2 times the clinical exposure at the recommended dose).

8.3 Nursing Mothers


Bicalutamide is not indicated for use in women.

8.4 Pediatric Use


The safety and effectiveness of bicalutamide in pediatric patients have not been established.

Labeling describing pediatric clinical studies for bicalutamide is approved for AstraZeneca Pharmaceuticals LP's bicalutamide tablet. However, due to AstraZeneca Pharmaceuticals LP's marketing exclusivity rights, a description of those clinical studies is not approved for this bicalutamide labeling.

8.5 Geriatric Use


In two studies in patients given 50 or 150 mg daily, no significant relationship between age and steady-state levels of total bicalutamide or the active R-enantiomer has been shown.

8.6 Hepatic Impairment


Bicalutamide should be used with caution in patients with moderate-to-severe hepatic impairment. Bicalutamide is extensively metabolized by the liver. Limited data in subjects with severe hepatic impairment suggest that excretion of bicalutamide may be delayed and could lead to further accumulation. Periodic liver function tests should be considered for hepatic-impaired patients on long-term therapy [see WARNINGS AND PRECAUTIONS ( 5.1)].

No clinically significant difference in the pharmacokinetics of either enantiomer of bicalutamide was noted in patients with mild-to-moderate hepatic disease as compared to healthy controls. However, the half-life of the R-enantiomer was increased approximately 76% (5.9 and 10.4 days for normal and impaired patients, respectively) in patients with severe liver disease (n=4).

8.7 Renal Impairment


Renal impairment (as measured by creatinine clearance) had no significant effect on the elimination of total bicalutamide or the active R-enantiomer.

8.8 Women


Bicalutamide has not been studied in women.

10 Overdosage


Long-term clinical trials have been conducted with dosages up to 200 mg of bicalutamide daily and these dosages have been well tolerated. A single dose of bicalutamide that results in symptoms of an overdose considered to be life threatening has not been established.

There is no specific antidote; treatment of an overdose should be symptomatic.

In the management of an overdose with bicalutamide, vomiting may be induced if the patient is alert. It should be remembered that, in this patient population, multiple drugs may have been taken. Dialysis is not likely to be helpful since bicalutamide is highly protein bound and is extensively metabolized. General supportive care, including frequent monitoring of vital signs and close observation of the patient, is indicated.

11 Description


Bicalutamide Tablets contain 50 mg of bicalutamide, a non-steroidal androgen receptor inhibitor with no other known endocrine activity. The chemical name is propanamide, N [4 cyano-3-(trifluoromethy])phenyl]-3-[(4-fluorophenyl) sulfonyl]-2-hydroxy- 2-methyl-,(+-). The structural and molecular formulas are:

Bicalutamide, USP has a molecular weight of 430.37. The pKaā€™ is approximately 12. Bicalutamide is a white to off-white powder which is practically insoluble in water at 37Ā°C (5 mg per 1000 mL), slightly soluble in chloroform and absolute ethanol, sparingly soluble in methanol, and soluble in acetone and tetrahydrofuran.

Bicalutamide is a racemate with its antiandrogenic activity being almost exclusively exhibited by the R-enantiomer of bicalutamide; the S-enantiomer is essentially inactive.

Each bicalutamide tablet intended for oral administration contains 50 mg of bicalutamide. In addition each tablet contains the following inactive ingredients: hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, povidone, sodium starch glycolate, and titanium dioxide.

12 Clinical Pharmacology


12.1 Mechanism of Action


Bicalutamide is a non-steroidal androgen receptor inhibitor. It competitively inhibits the action of androgens by binding to cytosol androgen receptors in the target tissue. Prostatic carcinoma is known to be androgen sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen.

When bicalutamide is combined with luteinizing hormone releasing hormone (LHRH) analog therapy, the suppression of serum testosterone induced by the LHRH analog is not affected. However, in clinical trials with bicalutamide as a single agent for prostate cancer, rises in serum testosterone and estradiol have been noted.

In a subset of patients who have been treated with bicalutamide and an LHRH agonist, and who discontinue bicalutamide therapy due to progressive advanced prostate cancer, a reduction in Prostate Specific Antigen (PSA) and/or clinical improvement (antiandrogen withdrawal phenomenon) may be observed.

12.3 Pharmacokinetics


Absorption

Bicalutamide is well-absorbed following oral administration, although the absolute bioavailability is unknown. Co-administration of bicalutamide with food has no clinically significant effect on rate or extent of absorption.

Distribution

Bicalutamide is highly protein-bound (96%) [see DRUG INTERACTIONS ( 7)].

Metabolism/Elimination

Bicalutamide undergoes stereospecific metabolism. The S (inactive) isomer is metabolized primarily by glucuronidation. The R (active) isomer also undergoes glucuronidation but is predominantly oxidized to an inactive metabolite followed by glucuronidation. Both the parent and metabolite glucuronides are eliminated in the urine and feces. The S-enantiomer is rapidly cleared relative to the R-enantiomer, with the R-enantiomer accounting for about 99% of total steady-state plasma levels.

Pharmacokinetics of the active enantiomer of bicalutamide in normal males and patients with prostate cancer are presented in Table 2.
Parameter Mean StandardĀ  Deviation
NormalĀ MalesĀ (n=30)
ApparentĀ OralĀ ClearanceĀ (L/hr) 0.320 0.103
SingleĀ DoseĀ PeakĀ ConcentrationĀ (mcg/mL) 0.768 0.178
SingleĀ DoseĀ TimeĀ toĀ Peak 31.3 14.6
ConcentrationĀ (hours)
Half-lifeĀ (days) 5.8 2.29
PatientsĀ withĀ ProstateĀ Cancer (n=40)
C s sĀ (mcg/mL) 8.939 3.504

13 Nonclinical Toxicology


13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility


Two-year oral carcinogenicity studies were conducted in both male and female rats and mice at doses of 5, 15 or 75 mg/kg/day of bicalutamide. A variety of tumor target organ effects were identified and were attributed to the antiandrogenicity of bicalutamide, namely, testicular benign interstitial (Leydig) cell tumors in male rats at all dose levels (the steady-state plasma concentration with the 5 mg/kg/day dose is approximately 2/3 human therapeutic concentrations *) and uterine adenocarcinoma in female rats at 75 mg/kg/day (approximately 1 1/2 times the human therapeutic concentrations *). There is no evidence of Leydig cell hyperplasia in patients; uterine tumors are not relevant to the indicated patient population.

A small increase in the incidence of hepatocellular carcinoma in male mice given 75 mg/kg/day of bicalutamide (approximately 4 times human therapeutic concentrations *) and an increased incidence of benign thyroid follicular cell adenomas in rats given 5 mg/kg/day (approximately 2/3 human therapeutic concentrations *) and above were recorded. These neoplastic changes were progressions of non-neoplastic changes related to hepatic enzyme induction observed in animal toxicity studies. Enzyme induction has not been observed following bicalutamide administration in man. There were no tumorigenic effects suggestive of genotoxic carcinogenesis.

A comprehensive battery of both in vitro and in vivo genotoxicity tests (yeast gene conversion, Ames, E. coli, CHO/HGPRT, human lymphocyte cytogenetic, mouse micronucleus, and rat bone marrow cytogenetic tests) has demonstrated that bicalutamide does not have genotoxic activity.

Administration of bicalutamide may lead to inhibition of spermatogenesis. The long-term effects of bicalutamide on male fertility have not been studied.

In male rats dosed at 250 mg/kg/day (approximately 2 times human therapeutic concentrations *), the precoital interval and time to successful mating were increased in the first pairing but no effects on fertility following successful mating were seen. These effects were reversed by 7 weeks after the end of an 11-week period of dosing.

No effects on female rats dosed at 10, 50 and 250 mg/kg/day (approximately 2/3, 1 and 2 times human therapeutic concentrations, respectively *) or their female offspring were observed. Administration of bicalutamide to pregnant females resulted in feminization of the male offspring leading to hypospadias at all dose levels. Affected male offspring were also impotent.

*Based on a maximum dose of 50 mg/day of bicalutamide for an average 70 kg patient.

14 Clinical Studies


14.1 Bicalutamide 50 mg Daily in Combination with an LHRH-A


In a multicenter, double-blind, controlled clinical trial, 813 patients with previously untreated advanced prostate cancer were randomized to receive bicalutamide 50 mg once daily (404 patients) or flutamide 250 mg (409 patients) three times a day, each in combination with LHRH analogs (either goserelin acetate implant or leuprolide acetate depot).

In an analysis conducted after a median follow-up of 160 weeks was reached, 213 (52.7%) patients treated with bicalutamide-LHRH analog therapy and 235 (57.5%) patients treated with flutamide-LHRH analog therapy had died. There was no significant difference in survival between treatment groups (see Figure 1). The hazard ratio for time to death (survival) was 0.87 (95% confidence interval 0.72 to 1.05).

Figure 1 - The Kaplan-Meier probability of death for both antiandrogen treatment groups

There was no significant difference in time to objective tumor progression between treatment groups (see Figure 2). Objective tumor progression was defined as the appearance of any bone metastases or the worsening of any existing bone metastases on bone scan attributable to metastatic disease, or an increase by 25% or more of any existing measurable extraskeletal metastases. The hazard ratio for time to progression of bicalutamide plus LHRH analog to that of flutamide plus LHRH analog was 0.93 (95% confidence interval, 0.79 to 1.10).

Figure 2 - Kaplan-Meier curve for time to progression for both antiandrogen treatment groups.

Quality of life was assessed with self-administered patient questionnaires on pain, social functioning, emotional well being, vitality, activity limitation, bed disability, overall health, physical capacity, general symptoms, and treatment related symptoms. Assessment of the Quality of Life questionnaires did not indicate consistent significant differences between the two treatment groups.

14.2 Safety Data from Clinical Studies using Bicalutamide 150 mg


Bicalutamide 150 mg is not approved for use either alone or with other treatments.

Two identical multicenter, randomized, open-label trials comparing bicalutamide 150 mg daily monotherapy to castration were conducted in patients that had locally advanced (T3-4, NX, MO) or metastatic (M1) prostate cancer.

Monotherapy ā€” M1 Group

Bicalutamide 150 mg daily is not approved for use in patients with M1 cancer of the prostate. Based on an interim analysis of the two trials for survival, the Data Safety Monitoring Board recommended that bicalutamide treatment be discontinued in the M1 patients because the risk of death was 25% (HR 1.25, 95% CI 0.87 to 1.81) and 31% (HR 1.31, 95% CI 0.97 to 1.77) higher in the bicalutamide treated group compared to that in the castrated group, respectively.

Locally Advanced (T3-4, NX, MO) Group

Bicalutamide 150 mg daily is not approved for use in patients with locally advanced (T3-4, NX, M0) cancer of the prostate. Following discontinuation of all M1 patients, the trials continued with the T3-4, NX, MO patients until study completion. In the larger trial (N=352), the risk of death was 25% (HR 1.25, 95% CI 0.92 to 1.71) higher in the bicalutamide group and in the smaller trial (N=140), the risk of death was 36% (HR 0.64, 95% CI, 0.39 to 1.03) lower in the bicalutamide group.

In addition to the above two studies, there are three other on-going clinical studies that provide additional safety information for bicalutamide 150 mg, a dose that is not approved for use. These are three multicenter, randomized, double-blind, parallel group trials comparing bicalutamide 150 mg daily monotherapy (adjuvant to previous therapy or under watchful waiting) with placebo, for death or time to disease progression, in a population of 8113 patients with localized or locally advanced prostate cancer.

Bicalutamide 150 mg daily is not approved for use as therapy for patients with localized prostate cancer who are candidates for watchful waiting. Data from a planned subgroup analysis of two of these trials in 1627 patients with localized prostate cancer who were under watchful waiting, revealed a trend toward decreased survival in the bicalutamide arm after a median follow-up of 7.4 years. There were 294 (37.7%) deaths in the bicalutamide treated patients versus 279 (32.9%) deaths in the placebo treated patients (localized watchful waiting group) for a hazard ratio of 1.16 (95% CI 0.99 to 1.37).

16 How Supplied/storage And Handling


Bicalutamide Tablets, USP 50 mg are white to off-white, round, biconvex, film-coated tablets, imprinted with "ZE 57" on one side and plain on other side and are supplied as follows:

NDC 68084-374-21 in unit dose packages of 30 (3x10)

16.1 Storage and Handling


Store at 20Ā° to 25Ā°C (68Ā° to 77Ā°F) [See USP Controlled Room Temperature].

17 Patient Counseling Information


Patients should be informed that therapy with bicalutamide and the LHRH analog should be started at the same time and that they should not interrupt or stop taking these medications without consulting their physician.

During treatment with bicalutamide, somnolence has been reported, and those patients who experience this symptom should observe caution when driving or operating machines.

Patients should be informed that diabetes, or loss of glycemic control in patients with pre-existing diabetes has been reported during treatment with LHRH agonists. Consideration should therefore be given to monitoring blood glucose in patients receiving bicalutamide in combination with LHRH agonists.

Patient Information Leaflet

Bicalutamide Tablets, USP

Read the Patient Information that comes with bicalutamide before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your healthcare provider about your medical condition or your treatment.

What is Bicalutamide?

Bicalutamide is a prescription medicine called an androgen receptor inhibitor, used in combination with lutenizing hormone-releasing hormone (LHRH) medicines to treat stage D2 metatastic prostate cancer. It is not known if bicalutamide is safe and effective in children.

Who should not take Bicalutamide?

Do not take bicalutamide if:
  • you are a woman.
  • you are allergic to any of the ingredients in bicalutamide. See the end of this leaflet for a complete ul of ingredients

What should I tell my healthcare provider before taking Bicalutamide?

Before you take bicalutamide, tell your healthcare provider about all your medical conditions including if you:
  • are a woman (see who should not take bicalutamide)
  • are pregnant or think you may be pregnant
  • have liver problems
  • take a medicine to thin your blood. Ask your healthcare provider or pharmacist if you are not sure if your medicine is a blood thinner.
  • have diabetes (poor blood sugar control has been reported in people taking bicalutamide in combination with LHRH medicines)

Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins and herbal supplements. Bicalutamide and other medicines may affect each other causing side effects. Bicalutamide may affect the way other medicines work, and other medicines may affect how bicalutamide works.

Know the medicines you take. Keep a ul of your medicines with you to show your healthcare providers when you get a new medicine.

How should I take Bicalutamide?
  • Take bicalutamide exactly as prescribed.
  • Take bicalutamide at the same time everyday.
  • Your treatment with bicalutamide should start at the same time as your treatment with the LHRH medicine
  • If you miss a dose do not take an extra dose, take the next dose at your regular time. Do not take 2 doses at the same time.
  • Bicalutamide can be taken with or without food.
  • If you take too much bicalutamide, call your healthcare provider or Poison Control Center or go to the nearest hospital emergency room right away.
  • Do not stop taking bicalutamide unless your healthcare provider tells you.
  • Your healthcare provider may do blood tests while you take bicalutamide.
  • Your prostate cancer may get worse while taking bicalutamide in combination with LHRH medicines. Regular monitoring of your prostate cancer with your healthcare provider is important to determine if your disease is worse.

What should I avoid while taking Bicalutamide?

Driving and operating machinery. Do not drive, operate machinery, or do other dangerous activities until you know how bicalutamide affects you.

What are the possible side effects of Bicalutamide?

Bicalutamide can cause serious side effects.

Get medical help right away, if you have:
  • trouble breathing with or without a cough or fever. Some people who take bicalutamide get an inflammation in the lungs called interstitial lung disease.
  • An allergic reaction. Symptoms of an allergic reaction include : itching of the skin, hives (raised bumps), swelling of the face, lips, tongue, throat, or trouble swallowing.
  • Yellowing of the skin and eyes (jaundice), dark urine, right upper stomach pain, nausea, vomiting, tiredness, loss of appetite, chills, fever, whole body pain. These may be symptoms of liver damage.
  • Poor blood sugar control can happen in people who take bicalutamide in combination with LHRH medicines.
  • enlargement of breast (gynecomastia) and breast pain

The most common side effects of bicalutamide include:
  • hot flashes, or short periods of feeling warm and sweating
  • whole body pain in your back, pelvis, stomach
  • feeling weak
  • constipation
  • infection
  • nausea
  • swelling in your ankles, legs or feet
  • diarrhea
  • blood in your urine
  • waking from sleep to urinate at night
  • a decrease in red blood cells (anemia)
  • feeling dizzy

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of bicalutamide. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

HOW SHOULD I STORE BICALUTAMIDE TABLETS?

Store bicalutamide tablets between 20Ā°C to 25Ā°C (68Ā°F to 77Ā°F).

Keep bicalutamide tablets and all medicines out of the reach of children.

General information about the safe and effective use of Bicalutamide Tablets.

Medicines are sometimes prescribed for purposes other than those uled in a patient information leaflet. Do not use bicalutamide for a condition for which it was not prescribed. Do not give bicalutamide to other people, even if they have the same symptoms that you have. It may harm them.

This patient information leaflet summarizes the most important information about bicalutamide. If you would like more information about bicalutamide talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about bicalutamide that is written for health professionals. Please address medical inquiries to, (MedicalAffairs@zydususa.com) Tel.: 1-877-993-8779.

What are the ingredients in Bicalutamide Tablets?

Active ingredients include: bicalutamide

Inactive ingredients include: hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, povidone, sodium starch glycolate, and titanium dioxide.


Manufactured by:

Cadila Healthcare Ltd.

Ahmedabad, India

Distributed by:

Zydus Pharmaceuticals USA Inc.

Pennington, NJ 08534

Repackaged by:

American Health Packaging

Columbus, Ohio 43217

Package Label.principal Display Panel


DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site